Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2652W HIGH $27.15
Volume
2.76 M
Value Traded
385.31 K
Short % Float
2.63%
-34.42%Week
-75.58%1 Month
-96.3%3 Month
-98.24%6 Month
-92.62%5 Year
-99.73%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
4.44 M
EPS (TTM)
27.04
P/E Ratio
0.01
Ent. Value
167.73 M
Total Shares
17.49 M
Float Shares
1.83 M
Insiders
89.54%
Institutions
1.62%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ENLV Catalyst Timeline
Dated clinical, regulatory and corporate events for Enlivex Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Enlivex Ltd.
445Total events
5Upcoming
80Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▼Partnership / LicenseCorporate
Enlivex terminates securities purchase agreement with Rain Foundation for private placement of 66,666,667 ordinary shares payable in RAIN tokens
◆Oral PresentationPresentation
Management webinar to discuss capital strategy, Rain protocol, and clinical milestones
◆R&D DayPresentation
Webinar to discuss capital strategy, Rain protocol, and clinical milestones
◆Quarterly UpdateAllocetraCorporate
Clinical update on ongoing Phase 2b trial in age-related knee osteoarthritis
age-related knee osteoarthritissource ↗
◆Enrollment UpdateAllocetraTrial
Progress update on Phase 2b trial in age-related knee osteoarthritis
age-related knee osteoarthritissource ↗
◆Enrollment UpdateAllocetraTrial
Ongoing Phase 2b trial in age-related knee osteoarthritis
age-related knee osteoarthritissource ↗
▲RMATAllocetraDesignation
FDA granted RMAT designation for Allocetra™ in knee osteoarthritis
symptomatic knee osteoarthritis in patients aged 64 and oldersource ↗
▲RMATAllocetraDesignation
FDA grants RMAT designation for Allocetra in age-related knee OA
age-related symptomatic knee osteoarthritissource ↗
▲Patent GrantedAllocetraIP / Competition
Issuance of Australian patent covering Allocetra™ for osteoarthritis
osteoarthritissource ↗
▲First Patient DosedAllocetraTrial
First patient dosed at U.S. clinical site in Phase 2b trial of Allocetra™ for knee OA
moderate-to-severe age-related symptomatic primary knee osteoarthritissource ↗
▲Topline ReadoutAllocetraClinical Data
Positive three-month and six-month topline data from Phase 2b stage of ENX-CL-05-001
moderate-to-severe knee osteoarthritissource ↗
◆Oral PresentationAllocetraPresentation
Oral presentation of 3-month and 6-month data from Phase IIa trial at EULAR 2026
knee osteoarthritissource ↗
●Oral PresentationPresentation
Enlivex to present quality longevity model powered by prediction markets treasury at Proof of Talk 2026
▲First Patient DosedAllocetraTrial
First patient dosed in Phase IIb study in the United States
knee osteoarthritissource ↗
▲First Patient DosedAllocetraTrial
First patient dosed in US for Phase 2b trial of Allocetra in knee osteoarthritis
moderate-to-severe age-related symptomatic primary knee osteoarthritissource ↗
◆Poster PresentationAllocetraPresentation
Poster presentation of 3-month and 6-month Phase IIa data for Allocetra at OARSI 2026
moderate-to-severe knee osteoarthritissource ↗
▲Other Regulator MilestoneAllocetraEx-US Regulatory
CTA approval by Danish Medicines Agency for Phase 2b trial of Allocetra
age-related primary moderate-to-severe knee osteoarthritissource ↗
▲IND ClearanceAllocetraIND
FDA clearance for Phase 2b trial of Allocetra
age-related primary moderate-to-severe knee osteoarthritissource ↗
▲Other Regulator MilestoneAllocetraEx-US Regulatory
DKMA approval received for Phase 2b trial of Allocetra
moderate-to-severe age-related symptomatic primary knee osteoarthritissource ↗
▲Equity OfferingCorporate
Exercised option to acquire 3,030,303,030 RAIN tokens at $0.0033/token
▲IND ClearanceAllocetraIND
FDA cleared IND for Phase 2b trial of Allocetra in knee osteoarthritis
age-related primary moderate-to-severe knee osteoarthritissource ↗
▲Debt Royalty FinancingCorporate
Consummation of $21 million debt financing with The Lind Partners
▲IND ClearanceAllocetraIND
FDA IND clearance received for Phase 2b trial of Allocetra
moderate-to-severe age-related symptomatic primary knee osteoarthritissource ↗
◆Trial InitiationAllocetraTrial
Phase IIb trial initiation planned for Allocetra in age-related primary knee OA
age-related primary knee osteoarthritissource ↗
◆R&D DayPresentation
Virtual Fireside Chat to discuss RAIN token strategy and Allocetra clinical development
▲Topline ReadoutAllocetraClinical Data
Positive 6-month topline data for Allocetra in knee OA
moderate to severe knee osteoarthritissource ↗
▼Equity OfferingCorporate
Enlivex announces $212M private placement for RAIN token treasury strategy
◆Management ChangeCorporate
Appointment of Matteo Renzi, former Prime Minister of Italy, to Board of Directors
▲Late-BreakerAllocetraPresentation
Late-breaking poster presentation of Phase IIa 3-month data at ACR Convergence 2025
moderate-to-severe knee osteoarthritissource ↗
▲Topline ReadoutAllocetraClinical Data
Phase IIa 3-month topline data readout for Allocetra in knee osteoarthritis
moderate-to-severe knee osteoarthritissource ↗
◆Oral PresentationAllocetraPresentation
KOL webinar discussing positive Phase IIa topline data for Allocetra in knee osteoarthritis
moderate-to-severe knee osteoarthritissource ↗
▲Topline ReadoutAllocetraClinical Data
Positive Phase IIa topline data for Allocetra in knee osteoarthritis
moderate-to-severe knee osteoarthritissource ↗
Past FDA Catalysts and PDUFA Decisions
How ENLV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-03 | Allocetra™ | Phase 2a data readout | Phase 2a |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$3M
Pipeline Value
Overvalued
Valuation Signal
1
Drugs Scored
0.4x
rNPV / MCap
Top 62%
Micro Cap(rank 408 of 658)
Percentile Rank
Enlivex Ltd. faces pipeline headwinds (32/100), with $214M risk-adjusted pipeline value, led by Allocetra in Primary Knee Osteoarthritis (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Allocetra Small moleculeCompletedNCT04612413 | Sepsis | Phase 2 | COMPLETED | 148 | Dec 16, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every ENLV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Allocetra RMAT | knee osteoarthritis | Phase 2a | 2026-06-01 | statistically significant improvement compared to the control placebo arm in reduction of pain and improvement of function in idiopathic age-related osteoarthritis patients (≥60 years)Read More | Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| John SmithCEO | Buy | 50,000 150,000 held | $45.50 | 01/10/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ENLV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in ENLV for Q2 2026. | ||||
ENLV Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ENLV ranks across every disease it competes in
Competitive Position is a premium feature
See how ENLV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialENLV News
ENLV▼ -6.7%on this news
Enlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
Enlivex Ltd. announced the termination of a securities purchase agreement with the Rain Foundation, which involved a private placement of 66,666,667 ordinary shares payable in RAIN tokens. The company exercised its termination rights and will not seek shareholder approval for the deal. This decision reflects potential challenges in their digital asset strategy amidst market volatility.
Read more →ENLV▼ -13.3%on this news
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
Enlivex Ltd. reported a significant increase in trading volume on its Rain protocol, reaching $860 million in July 2026, marking a 622% growth from June. The company anticipates further growth, projecting volumes to reach $1.3 billion in 2027 and $33 billion by 2029. Enlivex's dual strategy combines its clinical programs with a prediction markets treasury, aiming to enhance investor value.
Read more →ENLVEnlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
Enlivex Ltd. will host a webinar on July 30, 2026, to discuss its recent private placement, treasury strategy, and clinical advancements for Allocetra™, which has received RMAT designation from the FDA. The webinar will provide insights into the company's long-term strategy and ongoing clinical trials for age-related knee osteoarthritis.
Read more →ENLV▼ -47.4%on this newsshared move
Enlivex Announces $400,000,000 Private Placement
Enlivex Ltd. has announced a $400 million private placement of ordinary shares at a premium price. The funding will support its treasury strategy and the development of Allocetra™, an immunotherapy targeting age-related inflammatory conditions. The transaction is subject to shareholder approval and could potentially allow for an additional $400 million in shares to be purchased.
Read more →ENLVEnlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
Enlivex Ltd. has reported a net asset value (NAV) of $66.16 per ordinary share as of July 18, 2026. The company holds approximately $1.1 billion in RAIN tokens, reflecting its dual strategy of developing longevity therapeutics while engaging in digital asset markets. The update highlights both the company's strong asset position and the inherent risks associated with cryptocurrency volatility and regulatory uncertainties.
Read more →ENLVEnlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra™ in Age-Related Knee Osteoarthritis
Enlivex Ltd. has received FDA Regenerative Medicine Advanced Therapy designation for Allocetra™, aimed at treating age-related knee osteoarthritis in patients aged 64 and older. This designation supports the company's focus on a patient population that showed significant benefits in earlier trials. The company plans to advance Allocetra™ through a Phase IIb trial, with top-line data expected by mid-2027.
Read more →ENLVEnlivex Announces 1-for-15 Reverse Stock Split Effective July 9, 2026
Enlivex Ltd. announced a 1-for-15 reverse stock split effective July 9, 2026. This action will reduce the number of authorized shares and increase the par value per share. The reverse split aims to enhance the company's market presence and trading dynamics without affecting shareholders' ownership percentages. The company's shares will continue to trade under the symbol 'ENLV' on the Nasdaq Capital Market.
Read more →ENLVEnlivex Treasury Portfolio Update: Listing of the RAIN Token on Gate, One of the World's Largest Cryptocurrency Exchanges by Spot Trading Volume
Enlivex Ltd. announced the listing of its primary treasury asset, the RAIN token, on the Gate cryptocurrency exchange, effective June 24, 2026. This listing is expected to enhance the token's market access and liquidity, as Gate is ranked second globally in spot trading volume. Enlivex's treasury strategy focuses on acquiring RAIN tokens, which currently hold a significant total value.
Read more →ENLVEnlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.14 Billion
Enlivex Ltd. has reported holding 79,568,550,005 RAIN tokens valued at around $1.14 billion as of June 20, 2026. The company’s treasury metrics show a NAV per share of $4.67, reflecting its digital asset strategy. Enlivex is also advancing its Allocetra™ immunotherapy targeting inflammatory conditions associated with aging.
Read more →ENLVEnlivex Announces Issuance of Australian Patent Covering the Use of Allocetra™ in Patients with Osteoarthritis
Enlivex Ltd. announced the issuance of an Australian patent for Allocetra™, aimed at treating osteoarthritis. This patent enhances their intellectual property protection until at least 2040. The company has also initiated a Phase 2b clinical trial for Allocetra™ in patients with moderate-to-severe knee osteoarthritis, following positive results from earlier trials.
Read more →ENLVENLIVEX TO PRESENT QUALITY LONGEVITY MODEL POWERED BY PREDICTION MARKETS TREASURY AT PROOF OF TALK 2026
Enlivex Ltd. announced its participation as a Gold Sponsor at Proof of Talk 2026 in Paris, where CEO Dr. Oren Hershkovitz will present the company's unique model combining quality longevity therapeutics with a prediction markets treasury. The event will gather approximately 2,500 decision-makers from various sectors, highlighting the growing institutional interest in prediction markets. Enlivex aims to showcase its integrated approach to capital allocation and clinical development.
Read more →ENLV▲ +6.6%on this newsshared move
Allocetra Shows Durable 6-Month Efficacy in Knee Osteoarthritis Phase IIa Trial; Oral Presentation at EULAR 2026
Enlivex Ltd. announced that Allocetra showed durable efficacy in a Phase IIa trial for knee osteoarthritis, with results selected for an oral presentation at the EULAR 2026 congress. The trial demonstrated a statistically significant reduction in pain and improved function in patients aged 60 and above. The findings support the progression of Allocetra into a Phase IIb study.
Read more →ENLVEnlivex Treasury Portfolio Update: RAIN Holdings Valued at Approximately $1.16 Billion; Rain Foundation Appoints Industry Leaders to Advisory Board
Enlivex Ltd. announced a significant update regarding its RAIN token holdings, valued at approximately $1.16 billion. The Rain Foundation has appointed five industry leaders to its advisory board to support the growth of the Rain protocol. The protocol has gained traction with over 29,000 users and a $100 million liquidity commitment, making it the third-largest prediction market globally.
Read more →ENLV▲ +14.3%on this news· ran to +26% by day 3shared move
Enlivex Treasury Portfolio Update: Rain Protocol Jumps Into Top Three Global Prediction Markets In League Table Following $100M In Additional Liquidity
Enlivex Ltd. announced that its Rain protocol has secured a $100 million liquidity commitment, positioning it as the third-largest prediction market globally. This strategic move is expected to enhance market depth and infrastructure ahead of the FIFA World Cup. Enlivex holds a significant amount of RAIN tokens, reinforcing its treasury strategy.
Read more →ENLVEnlivex Announces Dosing Of First Patient In The United States As Part Of Its Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex Ltd. has announced the dosing of the first patient in the U.S. as part of its Phase 2b trial for Allocetra, targeting moderate-to-severe knee osteoarthritis. This trial follows FDA IND clearance and DKMA approval, aiming to evaluate the treatment's efficacy and safety. The trial involves multiple centers across the U.S., Denmark, and Poland, focusing on pain relief and quality of life improvements.
Read more →ENLVEnlivex Announces Receipt of Nasdaq Minimum Bid Price Notification
Enlivex Ltd. has received a notification from Nasdaq regarding its ordinary shares' bid price falling below the required $1.00 threshold. The company has a 180-day period to regain compliance by maintaining the minimum bid price for at least 10 consecutive business days. If compliance is not achieved, Enlivex may qualify for an additional compliance period or face potential delisting.
Read more →ENLVEnlivex Treasury Portfolio Update: Listing of the RAIN Token on HTX, a Leading Cryptocurrency Exchange
Enlivex Ltd. announced that its primary digital treasury asset, the RAIN token, has been officially listed on the HTX cryptocurrency exchange as of April 29, 2026. This development significantly improves the token's accessibility and liquidity, leveraging HTX's extensive user base and trading volume. Additionally, the company reported an increase in total RAIN holdings to approximately 78.8 billion tokens, valued at $567 million. Enlivex's strategy combines the use of RAIN for decentralized predictions while advancing clinical programs related to longevity, particularly targeting age-related conditions.
Read more →ENLV▼ -6.4%on this newsshared move
Enlivex Treasury Update: Total RAIN Holdings Rise to 78,819,756,062 Tokens as of April 27, 2026, Representing an Aggregated Value of $567 Million
Enlivex Ltd. announced an increase in its total RAIN token holdings to 78,819,756,062 tokens, valued at $567 million as of April 27, 2026. The acquisitions were completed at a substantial discount to the market price, reflecting the company's disciplined treasury strategy. CEO Oren Hershkovitz noted that this strategy aligns with a rising institutional interest in prediction markets. Enlivex is committed to leveraging its digital asset treasury alongside its clinical programs focused on longevity therapeutics.
Read more →ENLVEnlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
Enlivex Ltd. announced it will present clinical data from its Phase IIa trial of Allocetra™ at the OARSI 2026 World Congress. The data shows significant improvements in pain and function for patients with moderate-to-severe knee osteoarthritis. The presentations will be led by Prof. Philip Conaghan, highlighting the novel immunomodulating mechanism of Allocetra™.
Read more →ENLVEnlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex Ltd. has announced that it has secured regulatory approval from the Danish Medicines Agency for its Phase 2b clinical trial of Allocetra, aimed at treating moderate-to-severe knee osteoarthritis. This follows a similar approval from the FDA, marking a significant step in the company's global strategy. The trial will involve patient enrollment across multiple countries, including Denmark, the United States, and Poland. Allocetra's unique immunomodulatory mechanism aims to address inflammation associated with aging, potentially improving the quality of life for patients suffering from this common condition.
Read more →About Enlivex Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next ENLV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime